首页   按字顺浏览 期刊浏览 卷期浏览 Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexam...
Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma

 

作者: D. Peest,   H. Deicher,   R. Coldewey,   R. Leo,   R. Bartl,   H. Bartels,   H.J. Braun,   I.M. von Broen,   J.T. Fischer,   M. Gramatzki,   R. Hein,   R. Henke,   L. Hoffmann,   E.D. Kreuser,   W.D. Maier,   C.R. Meier,   J. Oertel,   M. Planker,   H.M. Reinhold,   E. Schäfer,   E. Schumacher,   K. Schumacher,   J. Selbach,   M. Stennes,   W. Stenzinger,   C. Tirier,   H. Wagner,   H.J. Weh,   J. Wysk,  

 

期刊: Onkologie  （Karger Available online 1990）
卷期: Volume 13, issue 6  

页码: 458-460

 

ISSN:0378-584X

 

年代: 1990

 

DOI:10.1159/000216820

 

出版商: S. Karger GmbH

 

关键词: Multiple myeloma;Induction therapy;Maintenance treatment

 

数据来源: Karger

 

摘要:

277 untreated multiple myeloma patients of stage I (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-α maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was > 36 months in stage II and 11 months in stage III patients.

 

点击下载:  PDF (1115KB)



返 回